fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Flecainide acetate

All products: general benefit

Jamp Flecainide · DIN 02493705 · 50 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Jamp Flecainide · DIN 02493705 Manufacturer: Jamp Pharma Corporation; listing date 2021-01-29 Health Canada: Marketed since 2020-10-27 · brand JAMP FLECAINIDE · ATC C01BC04 FLECAINIDE · form Tablet · route Oral · ingredients FLECAINIDE ACETATE 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Flecainide: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1389). What the ministry pays, not the patient.

Ministry pays: $0.1389 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493705)

Source record
DIN 02493705: Jamp Flecainide Raw flags: chronicUseMed=Y, sec3=Y Item: 240400119; group id 282; item number 0601; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1389; ministry $0.1389 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493705 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98370
Interchangeable products
Apo-Flecainide · DIN 02275538 · $0.1389 Auro-Flecainide · DIN 02459957 · $0.1389 Flecainide · DIN 02534800 · $0.1389 Mar-Flecainide · DIN 02476177 · $0.1389 NRA-Flecainide · DIN 02530066 · $0.1389 Tambocor · DIN 01966197 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (C01B, C01BC): coverage varies; not interchangeable

  • Propafenone (Rythmol): general benefit
  • Amiodarone (Cordarone): general benefit, not a benefit
  • Disopyramide (Norpace): general benefit, not a benefit, listing status unconfirmed
  • Mexiletine (Mexitil): general benefit, not a benefit
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:04 Cardiac Drugs

PROPAFENONE HCL

· 6 products · General benefit · strengths: 150mg, 300mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMLODIPINE

· 59 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications In patients without structural heart disease and with disabling symptoms, APO-FLECAINIDE is indicated for the prevention of: • paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal re-entrant tachycardia, atrioventricular re-entrant tachycardia and other supraventricular tachycardias of unspecified mechanism, • paroxysmal atrial fibrillation/flutter (PAF). Patients treated with APO-FLECAINIDE for supraventricular arrhythmias having impaired left ventricular function (ejection fraction < 40) and/or ischemic heart disease may be at increased risk for cardiac adverse reactions. Use of APO-FLECAINIDE in chronic atrial fibrillation has not been adequately studied and is not recommended (see 3 Serious Warnings and Precautions Box). APO-FLECAINIDE is also indicated for the treatment of: • documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgement of the physician, are life-threatening. • Because of the proarrhythmic effects of APO-FLECAINIDE, its use should be reserved for patients in whom, in the opinion of the physician, the benefits… https://pdf.hres.ca/dpd_pm/00083156.PDF PM date: JAN 13, 2026 Source product: APO-FLECAINIDE; DIN 02275538; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.